Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CEA-C082 | Human | ClinMax™ Human bFGF/FGF2 ELISA Kit | |||
GMP-FGCH17 | Human | GMP Human FGF basic Protein |
|
||
BFF-H5115 | Human | Human FGF basic (154aa) Protein, premium grade |
|
|
|
FGC-H81E3 | Human | Biotinylated Human FGF basic Protein, Avitag™,His Tag (HPLC verified) |
|
|
|
BFF-H4117 | Human | Human FGF basic Protein, premium grade |
|
|
GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) stimulates proliferation of NIH/3T3 cells. The specific activity of GMP Human FGF basic Protein is >2.50 x 10^6 IU/mg, which is calibrated against Basic Fibroblast Growth Factor WHO International Standard (NIBSC code: 90/712) (QC tested).
Human FGF basic, premium grade (Cat. No. BFF-H4117) stimulates proliferation of NIH/3T3 cells. The specific activity of Human FGF basic, premium grade is > 2.50×10^6 IU/mg, which is calibrated against human FGF basic WHO International Standard (NIBSC code: 90/712) (QC tested).
Immobilized Human Glypican 3, Fc Tag, low endotoxin (Cat. No. GP3-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Avitag,His Tag (Cat. No. FGC-H81E3) with a linear range of 0.6-10 ng/mL (QC tested).
The purity of Human FGF basic (154aa) Protein, premium grade (Cat. No. BFF-H5115) is more than 90% and the molecular weight of this protein is around 15-25 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Solid tumours; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Fibroblast growth factor 2 gene therapy (ID Pharma) | SeV-10101; SEV-10101; DVC-10101; BF-30 | Phase 2 Clinical | Dnavec | Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease | Details |
RBM-007 | ID3 (21); RBM-007; APT-F2 | Phase 2 Clinical | Ribomic | Achondroplasia; Macular Degeneration | Details |
This web search service is supported by Google Inc.